KR102164346B1 - Composition comprising fermented tea extract for anti-oxidation, anti-aging or anti-inflammation - Google Patents

Abstract

In the present specification, as a composition containing a fermented tea extract as an active ingredient, IL-1B (NM_000576), PTGS2 (NM_000963) and XDH ( An antioxidant composition, an anti-aging composition, and an anti-inflammatory composition for controlling the expression level of one or more selected from the group consisting of NM_000379) to a normal level are disclosed.
By using the antioxidant composition, anti-aging composition, or anti-inflammatory composition, it is possible to reduce damage to skin cells by returning the gene expression level changed by the stimulator causing oxidation, inflammation or aging to a normal level.

Description

Composition comprising fermented tea extract for anti-oxidation, anti-aging or anti-inflammation}

Antioxidant, anti-aging and anti-inflammatory compositions are disclosed herein. More specifically, a fermented tea extract that significantly changes the biomarker, a skin cell gene whose expression level is changed by aging and inflammation compared to normal skin cells, reduces the oxidation, aging and inflammation of skin cells. A composition comprising is disclosed.

These days, artificial temperature control of cooling/heating according to changes in the environment or lifestyle patterns, various stresses occurring in social life and skin stress due to environmental pollution, frequent cleansing according to makeup habits, and natural skin according to age increase Inflammation and skin aging are occurring.

In addition, excessive physical and chemical irritation, ultraviolet rays, and stress from the outside reduce the normal function of the skin and promote phenomena such as loss of elasticity, keratinization, wrinkle formation, and inflammation.In particular, ultraviolet rays, yellow dust or dust stimulate oxidation. It is a source of irritation of aging or inflammation.

Interleukin 1 is classified as a senescence-associated secretory phenotype (SASP), and in particular, interleukin 1b (IL-1b) is known to be involved in cellular senescence as a representative senescence marker (non-patented See document 1). It is known that IL-1b and PTGS2 are involved in skin inflammation, and XDH represents oxidative stress induced when exposed to an irritant for a long time, and as a result, is an indicator of exogenous skin aging (see Non-Patent Document 2). ). In addition, it is known that PTGS2 (=COX-2) is improved in skin cells exposed to irritants in relation to skin inflammation (see Non-Patent Document 3), and xanthine dehydrogenase (XDH) is an oxidative stress in the skin. stress), it is also known to be involved in skin aging. The above documents are incorporated by reference in their entirety as part of this specification.

Jean-Philippe Coppe, et al, "The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression", Annual Review of Pathology: Mechanisms of Disease, volume 5, 2010. Kim, H.J., et al, "Transcriptome analysis of airborne PM2.5-induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35, 2017. Natalia D Magnani, et al, "Skin Damage Mechanisms Related to Airborne Particulate Matter Exposure", toxicological sciences, 149(1), 2016, 227-236.

Accordingly, the present inventors have found that irritants causing oxidation, inflammation or aging have a detrimental effect on the skin, and these effects affect the expression of skin cell genes, resulting in symptoms such as skin cell oxidation, aging and inflammation. Do.

Accordingly, in one aspect, the present invention aims to provide an antioxidant composition, an anti-aging composition and an anti-inflammatory composition.

In order to achieve the above object, in one aspect, the present invention is a composition comprising a fermented tea extract as an active ingredient, IL- 1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379) It provides an antioxidant composition, an anti-aging composition and an anti-inflammatory composition for controlling the expression level of one or more selected from the group consisting of a normal level.

In one aspect, by using the antioxidant composition, anti-aging composition and anti-inflammatory composition provided by the present invention, it is possible to reduce damage to skin cells by returning the amount of gene expression changed by inflammation or aging stimulation to a normal level.

Figure 1 shows the cell viability by stimulus treatment, where ADSP represents yellow dust as Asian dust storm particles, and PM10 (Particulate matter 10) represents fine dust having a particle size of 10 μm. , PM2.5 (Particulate matter 2.5) represents fine dust with a particle size of 2.5㎛.
FIG. 2A shows an increase in the mRNA expression level of the IL-1B gene in skin cells subjected to stimulation to cause oxidation, inflammation or aging, and returns to a normal level by treatment with fermented tea.
Figure 2b shows the increase in the mRNA expression level of the PTGS2 gene in skin cells to which stimulation causing oxidation, inflammation or aging is applied, and returns to the normal level by treatment with fermented tea.
Figure 2c shows the increase in the mRNA expression level of the XDH gene in skin cells to which stimulation causing oxidation, inflammation or aging is applied, and returns to the normal level by treatment with fermented tea.
FIG. 3 is a result of analyzing fermented tea components through liquid chromatography-mass spectrometry (High Resolution LC-MS), and is a chromatogram of the raw material TIC, the quinic acid in the raw material, and the quinic acid standard product.

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, the composition may include a fermented tea extract as an active ingredient.

The term "fermented tea" as used herein refers to tea in a fermented state, and specifically refers to post-fermented tea.

As used herein, “post-fermented tea” refers to tea fermented and aged using microorganisms under conditions such as suitable moisture and temperature.

In one aspect, the post-fermented tea used in the present specification may be included as a pulverized product of the post-fermented tea itself or a dry pulverized product of the post-fermented tea, but is not limited thereto.

In one aspect of the present invention, the fermented tea may include quinic acid.

In the antioxidant, anti-aging or anti-inflammatory composition according to an embodiment of the present invention, the 　 tea may be green tea. In another aspect of the present invention, the 　 tea may be fermented green tea.

In one aspect, the fermented tea may be fermented and aged.

In one aspect, the fermented tea may be obtained by naturally fermenting tea leaves in which an internal enzyme is inactivated.

In one aspect of the present invention, the fermented tea may be extracted with a specific extraction solvent to form a fermented tea extract.

In one aspect of the present invention, the fermented tea extract may be prepared by extracting fermented tea with water or an organic solvent. Specifically, the fermented tea is selected from the group consisting of water, C ₁ -C ₆ anhydrous or aqueous lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and hexane. It can be prepared by extraction with an extraction solvent.

In one aspect, the fermented tea extract may be extracted at room temperature.

In one aspect, the fermented tea extract may be obtained by additionally performing one or more of filtration, concentration, separation, or drying after being extracted with the extraction solvent. In particular, the fermented tea extract may have undergone one or more filtration processes, and in one embodiment, two filtration processes are performed.

In one embodiment, the separation process may include a centrifugation process.

Specifically, the extraction includes water, an anhydrous or hydrous lower alcohol of C ₁ -C ₆ , a polar solvent including acetone and butylene glycol, and ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and hexane. Any one or more of the low polarity solvents may be used as the solvent.

More specifically, the solvent may be a 50-90% aqueous ethanol solution, 60-80% or 65-75% ethanol aqueous solution. When the solvent is a 50-90% aqueous ethanol solution, the active ingredient can be effectively extracted from the fermented tea. In one embodiment, the solvent may be about 70% aqueous ethanol solution.

In one aspect, the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.

However, the fermented tea extract according to the present invention can be obtained by extraction by a conventional method in the art, and is not limited by the above-described method.

In one aspect of the present invention, in the composition, the composition may include a fermented tea extract in an amount of 0.000001 to 30% by weight based on the total weight of the composition. When the content is 0.000001 to 30% by weight, the antioxidant, anti-aging and anti-inflammatory effects of the fermented tea extract were excellent.

Specifically, 0.0000001 wt% or more, 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt% or more, 0.00001 weight % Or more, 0.00003% or more, 0.00005% or more, 0.00007% or more, 0.00009% or more, 0.0001% or more, 0.0003% or more, 0.0005% or more, 0.0007% or more, 0.0009% or more, 0.001% or more % Or more, 0.01% or more, 0.1% or more, 1% or more, 3% or more, 5% or more, 7% or more, 9% or more, 10% or more, 13% or more, 15% % Or more, 17 wt% or more, 19 wt% or more, 21 wt% or more, 23 wt% or more, 25 wt% or more, 27 wt% or more, 29 wt% or more, 30 wt% or more, 31 wt% or more, 32% or less, 31% or less, 30% or less, 29% or less, 28% or less, 26% or less, 24% or less, 22% or less, 20% or less, 18% or less, 16% or less, 14% or less, 12% or less, 10% or less, 9% or less, 8% or less, 6% or less, 4% or less, 2% or less, 1% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less, 0.006 wt% or less, 0.001 wt% or less, 0.0009 wt% or less, 0.0007 wt% or less, 0.00005 wt% or less, 0.00003 wt% or less, 0.00001 wt% or less, 0.000009 wt% or less, 0.000007 wt% or less, 0.000005 wt% or less, 0.000003 wt% or less, 0.000001 wt% or less Below, 0.0000009 wt% or less, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, 0.00000009 wt% or less, but is not limited thereto.

Another aspect of the present invention includes the anti-oxidant, anti-aging and anti-inflammatory uses of the compositions of the present invention.

In one aspect, the present invention provides a composition for inhibiting oxidation, inflammation or aging by controlling the expression level of a specific gene in skin cells damaged by oxidation, inflammation or senescence stimulation to a normal level.

In one aspect, the composition may be applied to keratinocytes.

In one aspect, specifically, in the present invention, genes in skin cells whose expression levels are affected by stimulation of oxidation, inflammation or aging include IL-1B (NM_000576), PTGS2 (NM_000963), XDH (NM_000379), and the like. Since IL-1B (NM_000576), PTGS2 (NM_000963), and XDH (NM_000379) are genes whose expression levels are increased by stimulation of oxidation, inflammation or aging, the oxidation of skin cells by inhibiting the expression levels of these genes and regulating them to normal levels. , Inhibits inflammation or aging.

In one aspect, genes whose expression levels are increased by stimulation of oxidation, inflammation or aging used in the present invention are shown in [Table 1]. In the table, Name means NCBI's genebank accession ID, Gene Symbol means the official gene symbol, and Gene title means the name of each gene.

Increase gene Name Gene
Symbol Gene title NM_000576 IL1B interleukin 1, beta NM_000963 PTGS2 Cyclooxygenase-2 (COX-2) NM_000379 XDH xanthine dehydrogenase

Analysis of the expression level of the gene or protein includes microarray, PCR, NGS (Nest Generation Sequencing; next-generation sequencing), Western blot, Northern blot, ELISA, radioimmunoassay, radioimmuno diffusion method, tissue immunostaining, immunoprecipitation analysis, etc. It can be analyzed using a variety of analysis methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

The cosmetic composition includes, for example, various creams, lotions, various creams, lotions, and cosmetics such as skins, cleansing, face wash, soap, and beauty liquids.

In one aspect, the cosmetic composition to which the composition containing the fermented tea extract of the present invention is added may take the shape of a solution, an emulsion, a viscous mixture, or the like.

That is, the cosmetic as an aspect of the present invention is not particularly limited in its formulation, and for example, emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, essence, cleansing Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, conditioner, body cleaner, soap, hair dye, spray, etc. may be mentioned.

In the cosmetic composition of each formulation, other ingredients other than the fermented tea extract may be appropriately selected and blended by a person skilled in the art without difficulty according to the formulation or purpose of use of other cosmetic materials.

In addition, the cosmetic as an aspect of the present invention may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo lipids, and seaweed extract.

In one aspect, in the cosmetic composition of the present invention, in addition to the essential ingredients, other ingredients which are usually blended in the cosmetic may be blended as needed.

Other ingredients that may be added include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, Blood circulation accelerators, cold sensation agents, restrictors, and purified water.

In addition, the blending components that may be added are not limited thereto, and any of the above components can be blended within a range that does not impair the object and effect of the present invention.

In one aspect, the pharmaceutical composition comprising the fermented tea extract of the present invention may further include an appropriate carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions.

As the dosage form, the pharmaceutical composition containing the fermented tea extract may include oral preparations such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays according to a conventional method. It can be formulated and used in any form suitable for pharmaceutical preparations.

In general, it should be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various related factors such as the severity of symptoms, the selected route of administration, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 3000 mg/kg/day, for example, 10 mg/kg/day to 500 mg/kg/day.

In the health functional food composition as an aspect of the present invention, the health food is manufactured using nutrients that are easily deficient in daily meals or raw materials or ingredients (functional ingredients) having useful functions for the human body, and maintains the normal function of the human body Or it may refer to food that maintains and improves health through activation of physiological functions, but is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., but is not limited thereto and may be manufactured and processed in any form according to laws.

Specifically, the health drink composition is not particularly limited to other ingredients other than containing the compound as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as an additional ingredient, such as a conventional beverage. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharide, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various related factors such as the severity of symptoms, the selected route of administration, the age, sex, weight, and health status of the subject. . In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 1000 mg/kg/day, for example, 0.02 mg/kg/day to 6 mg/kg/day.

Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples. However, these examples are provided for illustrative purposes only to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Manufacture of fermented tea

1-1 fermentation stage

Fermented tea was prepared by stacking dried green tea leaves thick, and naturally fermented by creating a high temperature and humid environment so that the moisture content of green tea leaves could be 30-50%. The prepared green tea leaves were fermented for 6 weeks at a temperature of 45°C.

1-2 ripening stages

Fermented tea fermented in the 1-1 fermentation step was put in Jeju Onggi and aged for 50 days to prepare fermented tea.

[Example 2] Analysis of components of fermented tea

The fermented tea components prepared in Example 1 were analyzed through a liquid chromatography-mass spectrometer (Q Exactive High Resolution LC-MS) of Thermo. As can be seen from the chromatogram of FIG. 3, the quinic acid standard was detected at 0.65 minutes and theoretically had a value of m/z 191.05556 in negative ion mode. When ion extraction in the range of molecular weight from 191.05400 to 191.05650 in anion mode TIC (negative ion mode TIC) of fermented tea, a peak was detected at RT 0.65 min. The peak exhibited a m/z value of 191.05505, which is a value within the theoretical m/z of 191.05556 of quinic acid and an error ppm of 2.6, and can be seen with the same molecular weight to the fourth decimal place. Therefore, the peak at 0.65 minutes in the raw material can be identified as quinic acid.

[Example 3] Preparation of fermented tea extract

The fermented tea of Example 1 was extracted at room temperature using an extraction solvent in which purified water and ethanol were mixed in a ratio of 3:7, that is, 70% ethanol as an extraction solvent. After extraction at room temperature, primary filtration was performed to remove the solid material contained in the extract, and then the extract was concentrated to remove ethanol, and this was separated and purified. Then, after centrifugation and secondary filtration, the mixture was dried to obtain a fermented tea extract.

[Example 4] Preparation of oxidation, aging and anti-inflammatory stimulants

A low volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, USA) was used to collect fine dust, which is a source of oxidation, aging and anti-inflammatory stimuli, and the filter pack was used to remove the filter and denude around 10 a.m. on every measurement day. After replacement, samples were collected for about 24 hours. For 28 days, fine dust was collected every day at Punghaji Station in Seoul (located in Cheoin-gu, Yongin-si, Gyeonggi-do, on the 6th floor of the dormitory of Hankuk University of Foreign Studies Research Center for Foreign Studies), and the measurement time is measured by starting the timer while turning on the vacuum pump and turning off the vacuum pump. The time was recorded. The sampling flow rate was 16.7 L/min, and the flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the beginning of the measurement, and the flow rate was measured again at the end of the measurement. The weight of the Teflon filter in the filter pack was measured before and after sample collection. Before measuring the weight of the Teflon filter, put a constant weight in a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours, and then measure the weight twice on an electronic scale (DVG215CD, Ohaus) with 5 decimal places to calculate the average value. Recorded. Even after collecting the sample, the weight was measured twice in a desiccator for 24 hours before measuring the weight, and the mass concentration was calculated by comparing it with the weight measured before collection. The extraction of fine dust was carried out by soaking a Teflon filter in 1 mL of ethanol, adding 14 mL of DW, closing the lid while making the aerosol collection surface of the filter contact the water surface, and applying ultrasonic waves for 30 minutes with an ultrasonic cleaner. In order to minimize the error due to moisture in the filtration step, after completely removing moisture from the filter for 48 hours in a decicator, weigh the filter using an ultra-precise scale (Mettler Toledo Company) that can measure up to 0.1 mg. Weighed and weighed before and after extraction of the filter.

[Example 5] Cultivation of (normal human) keratinocyte line

(Normal human) keratinocytes were purchased from Lonza (Lonza, Inc., Walkersville, MD, USA), subcultured, and subcultured in a CO2 incubator at 37°C and 5% CO2. Cultured. The cell culture medium was in accordance with Lonza's guidelines. KGM-2 bullet kit CC-4152 (KGM TM-2 Bullet kit, CC-4152) (ingredient: BPE (Bovine pituitary extract)), human epidermis growth in 500 ml of KBM-2 (KBMTM-2, CC-3103) medium Human epidermal growth factor (hEGF), Insulin, Hydrocortisone, Transferrin, Epinephrine, and Gentamicin Sulfate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA) -1000)) was added to the KGM-2 bullet kit CC-3107 (KGM TM-2 Bullet Kit, CC-3107).

[Example 6] (Normal human) keratinocyte treatment and cytotoxicity measurement

In order to confirm the cytotoxicity through treatment with the stimulus, the MTT experiment was performed using a (normal human) keratinocyte line by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983).

Specifically, a 24-well plate was used and fine dust having a diameter of 2.5 μm obtained by collecting in Example 4 was dispersed in purified water to prepare a fine dust dispersion, and then 2.5 × 10 ^{5 in} the cell culture conditions of Example ⁵ Cells cultured under the condition of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours, followed by mixing 5 mg/ml of 3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide (MTT), Incubated for an additional 3 hours at ℃. After that, the medium was removed and the formed formazan crystal was dissolved in 500 µl of DMSO. The lysate was transferred to a 96-well plate, aliquoted, and the OD value was measured at an absorbance of 540 nm. The measurement results are shown in FIG. 1.

As shown in Fig. 1, the concentration (IC20) value showing 80% viability against cytotoxicity by a dispersion in which fine dust of 2.5 micrometers or less is dispersed in the cell line is 12.5 μg/in the case of an aqueous extract of fine dust of 2.5 micrometers or less. It was ml.

[Example 7] Confirmation of cell gene change in fine dust through Next Generation Sequencing

For RNA-sequencing data processing and analysis, reference was made to the general analysis steps developed by Trapnell et al. (2012). RNA-seq data quality was checked using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) was used. Thus, base and adapter sequences with poor accuracy were removed. Thereafter, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the data amount of each sample was confirmed using EVER-seq, renamed RSeQC (Wang et al., 2012). ). In addition, expression levels of transcripts were quantified using Cufflinks, and the levels of transcription were compared between samples treated with fine dust dispersion and normal samples (Trapnell et al., 2010). FDR adjusted p-value<0.05, a strict cutoff of ≥2.0 fold-change was applied to determine a gene that showed a significant difference in expression when the dispersion of fine dust having a diameter of 2.5 μm was treated. The measurement results are shown in the following [Table 2] and [FIGS. 2A] to [FIG. 2C].

Increase gene Name Gene
Symbol Drainage change NM_000576 IL1B 10.7 NM_000963 PTGS2 3.7 NM_000379 XDH 2.4

[Example 8] Real-time RT-PCR quantification

Microdust with a diameter of 2.5 μm extracted in Example 4 was treated with 12.5 μg of human normal keratin skin cells cultured in Example 5 in 1 ml of cell culture medium, and the primers of the genes shown in Table 3 below (applied biosystems) TaqMan® Primers) was used to measure the relative amount of mRNA expression. The fermented tea extract was prepared in Example 2.

Increase gene Name Gene
Symbol TaqMan® primer NM_000576 IL1B Hs01555410_m1 NM_000963 PTGS2 Hs00153133_m1 NM_000379 XDH Hs00166010_m1

After 24 hours of treatment with the fermented tea extract in the medium at a concentration of 20 ppm, the culture medium was removed, and the cells were washed with 2 ml of Phosphate Buffered Saline (PBS), and then Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used to isolate intracellular RNA. The isolated RNA was purified once again with QIAGEN's RNA kit (QIAGEN RNeasy kt, QIAGEN, Valencia, CA), and then Agilent's Bioanalyzer 2100 model instrument (Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, CA, USA) ) Was used to check the quality of RNA. CDNA was synthesized from the RNA using Invitrogen's Superscript Reverse Transcriptase (RT) kit, Invitrogen, Carlsbad, CA, and this was obtained by using the primers of [Table 3] in real time reverse transcription polymerase chain reaction (Q -RT-PCR: real time-reverse transcription polymerase chain reaction). Gene expression pattern changes were evaluated by real-time PCR using Applied Biosystems' TaqMan gene expression system (TaqMan gene expression assay kit, Applied Biosystems, Foster City, CA), and the results were evaluated by real-time PCR [Fig. 2A] To [Fig. 2c]. Both Q-RT-PCR and real-time PCR used were performed according to the standard protocol distributed by Life Technology, and specifically, after treatment at 95°C for 20 seconds, processing at 95°C for 3 seconds and 60°C for 30 seconds Was performed for 40 cycles.

As shown in [Fig. 2a] to [Fig. 2c], there is a gene whose expression level is increased or decreased in skin cells stimulated by fine dust, and interleukin 1 beta (IL-1B) by treatment with fermented tea extract, It was confirmed that the expression levels of prostagladin-endoperoxide synthase 2 (PTGS2) and xanthine dehydrogenase (XDH) genes were decreased.

Therefore, the fermented tea extract effectively protects skin cells from skin cell damage caused by oxidation, inflammation or aging stimulation, and inhibits or prevents changes in the expression level of the specific genes described above by the oxidation, inflammation or aging stimulation, It can be seen that it can be made to have a level of expression.

Hereinafter, examples of the formulation of the composition according to the present invention will be described, but cosmetic compositions, pharmaceutical compositions, and health functional food compositions can be applied in various formulations, which are not intended to limit the present invention, but are intended to be described in detail. .

[Formulation Example 1] Tablet

After mixing 100 mg of fermented tea extract, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate according to an embodiment of the present invention, tablets were prepared by tableting according to a conventional tablet preparation method.

Ingredients Content(mg) Fermented tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 2] Capsule

After mixing 100 mg of fermented tea extract, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate according to an embodiment of the present invention, a capsule was prepared by filling in a gelatin capsule according to a conventional capsule preparation method.

Ingredients Content(mg) Fermented tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2

[Formulation Example 3] Granules

50 mg of fermented tea extract according to an embodiment of the present invention, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, molded into granules using a fluid bed granulator, and then filled into a cloth.

Ingredients Content(mg) Fermented tea extract 50 Anhydrous glucose 250 Starch 550

[Formulation Example 4] Soap

Ingredients content(%) Fermented tea extract 5.00 maintain Appropriate amount Sodium hydroxide Appropriate amount Sodium chloride Appropriate amount Spices Appropriate amount Purified water Balance

[Formulation Example 5] Lotion

Ingredients content(%) Fermented tea extract 5.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Water-soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 Citric acid 0.05 Licorice extract 0.20 1,3-butylene glycol 3.00 Purified water Balance

[Formulation Example 6] Cream

Ingredients content(%) Fermented tea extract 3.00 Polyethylene glycol monostearate 2.00 Self-emulsifying type glycerin monostearate 5.00 Cetyl alcohol 4.00 Squalene 6.00 Glyceryl tri2-ethylhexanoate 6.00 Sphingoglycolipid 1.00 1.3-butylene glycol 7.00 Purified water Balance

[Formulation Example 7] Ointment

Ingredients content(%) Fermented tea extract 5.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-phosphate magnesium salt 1.00 Lauroylhydroxyproline 1.00 Water-soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water Balance

[Formulation Example 8] Preparation of essence

Ingredients content(%) Fermented tea extract 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 Dark glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water Balance

[Formulation Example 9] Health Food

Ingredients content Fermented tea extract 2mg Vitamin A acetate 70μg Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B12 0.2μg Vitamin C 10mg Biotin 10μg Nicotinic acid amide 1.7mg Folic acid 50μg Calcium pantothenate 0.5mg Ferrous sulfate 1.75mg Zinc oxide 0.82mg Magnesium carbonate 25.3mg Potassium Phosphate Monobasic 15mg Dicalcium phosphate 55mg Potassium citrate 90mg Calcium carbonate 100mg Magnesium chloride 24.8mg

[Formulation Example 10] Health Drink

Ingredients content Fermented tea extract 50mg Citric acid 1000mg oligosaccharide 100 g Taurine 1g Purified water Balance

Claims (16)

Contains fermented tea extract as an active ingredient, inhibiting the expression of one or more selected from the group consisting of IL-1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379), oxidation of the skin due to fine dust, loss of elasticity, A cosmetic composition for suppressing keratinization, wrinkles or inflammation. Contains fermented tea extract as an active ingredient, inhibiting the expression of one or more selected from the group consisting of IL-1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379), oxidation of the skin due to fine dust, loss of elasticity, A health functional food composition for suppressing keratinization, wrinkle formation or inflammation. A pharmaceutical composition for inhibiting skin inflammation due to fine dust, containing fermented tea extract as an active ingredient, and inhibiting the expression of at least one selected from the group consisting of IL-1B (NM_000576), PTGS2 (NM_000963) and XDH (NM_000379) . The method of claim 1,
The fermented tea is naturally fermented tea leaves in which internal enzymes are inactivated. The method of claim 1,
The fermented tea extract is contained in an amount of 0.000001 to 30% by weight based on the total weight of the composition. The method of claim 1,
The fermented tea extract is water, C ₁ -C ₆ anhydrous or water-containing lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and any one or more extractions selected from the group consisting of hexane The composition is extracted with a solvent. delete The method of claim 1,
The composition is applied to keratinocytes. The method of claim 3,
The fermented tea extract is administered in a dosage of 10 to 500 mg / kg / day, composition. The method of claim 2,
The fermented tea is naturally fermented tea leaves in which internal enzymes are inactivated. The method of claim 2,
The fermented tea extract is contained in an amount of 0.000001 to 30% by weight based on the total weight of the composition. The method of claim 2,
The fermented tea extract is water, C ₁ -C ₆ anhydrous or water-containing lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and any one or more extractions selected from the group consisting of hexane The composition is extracted with a solvent. The method of claim 2,
The fermented tea extract is consumed in an amount of 0.02 to 6 mg/kg/day, composition. The method of claim 3,
The fermented tea is naturally fermented tea leaves in which internal enzymes are inactivated. The method of claim 3,
The fermented tea extract is contained in an amount of 0.000001 to 30% by weight based on the total weight of the composition. The method of claim 3,
The fermented tea extract is water, C ₁ -C ₆ anhydrous or water-containing lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, and any one or more extractions selected from the group consisting of hexane The composition is extracted with a solvent.

Images